Ferroptosis-centered Disease Response Information
General Information of the Disease (ID: DIS00082)
| Name |
Neuropathic pain
|
||||
|---|---|---|---|---|---|
| ICD |
ICD-11: 8E43
|
||||
Full List of Target(s) of This Ferroptosis-centered Disease
Solute carrier family 40 member 1 (SLC40A1)
| In total 1 item(s) under this target | |||||
| Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target | [1] | ||||
| Target for Ferroptosis | Marker/Suppressor | ||||
| Responsed Disease | Neuropathic pain [ICD-11: 8E43] | ||||
| Responsed Regulator | NAD-dependent protein deacetylase sirtuin-2 (SIRT2) | Suppressor | |||
| Pathway Response | Fatty acid metabolism | hsa01212 | |||
| Ferroptosis | hsa04216 | ||||
| Cell Process | Cell ferroptosis | ||||
| In Vivo Model |
About 70 adult male Sprague-Dawley rats weighing 200-250 g were used in the animal model. Rats were anesthetized with 5% isoflurane by a small animal anesthesia machine and maintained with 2-3% isoflurane. The rats were placed in a left decubitus position; approximately 1 cm below the right iliac bone, the three branches of the sciatic nerve were exposed: the tibial nerve, common peroneal nerve, and sural nerve.
Click to Show/Hide
|
||||
| Response regulation | An intrathecal injection of SIRT2 overexpressed recombinant adenovirus, which upregulated the expression of SIRT2, attenuated mechanical allodynia, enhanced the level of FPN1, inhibited intracellular iron accumulation, and reduced oxidant stress levels, thereby reversing the changes to ACSL4 and GPX4 expression in the SNI rats. This evidence suggests that SIRT2-targeted therapeutics may help relieve the symptoms of chronic neuropathic pain (NP). | ||||